Transcriptomic analysis identifies a potential target for bevacizumab resistant glioblastoma.

Lodha R, Muller-Greven G, Maqbool MA, Guo L, Buchan G, Singh K, Qadan MA, Chelakkot VS, Decker PA, Bakken K, Carlson BL, Burgenske D, Nowacki AS, Vasmatzis G, Kizilbash SH, Sarkaria JN, Gladson CL

The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts.

Xue Z, Mladek AC, Rathi S, Jain S, Vaubel RA, Odukoya LA, Garcia DA, Liu L, Bakken KK, Carlson BL, Ott LL, Burgenske DM, Hu Z, Dragojevic S, Decker PA, Kosel ML, Breen WG, Gupta SK, Eckel-Passow JE, Elmquist WF, Zhong W, Sarkaria JN

The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors.

Zhang W, Grams MP, Oberoi RK, Oh JH, Decker PA, Sio TT, Talele S, Wilson ZC, Connors MA, Bakken KK, Carlson BL, Ott LL, Burgenske DM, Tryggestad EJ, Eckel Passow JE, Elmquist WF, Sarkaria JN

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma.

Vaubel RA, Zhang W, Oh JH, Mladek AC, Pasa TI, Gantchev JK, Waller KL, Baquer G, Stopka SA, Regan MS, Hossain MA, Decker PA, Kosel ML, Gupta SK, Jain S, Sarkaria PP, Hu Z, Ott LL, Carlson BL, Bakken KK, Talele S, Zhang W, Ligon KL, Lee EQ, Eckel Passow JE, Burgenske DM, Agar NYR, Elmquist WF, Sarkaria JN

DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits.

Dragojevic S, Smith EJ, Regan MS, Stopka SA, Baquer G, Xue Z, Zhang W, Connors MA, Kloeber JA, Hu Z, Bakken KK, Ott LL, Carlson BL, Burgenske DM, Decker PA, Tian S, Gupta SK, Laverty DJ, Eckel-Passow JE, Elmquist WF, Agar NYR, Nagel ZD, Sarkaria JN, Callaghan CM

Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628.

Garcia DA, Rathi S, Connors MA, Grams M, Vaubel RA, Bakken KK, Ott LL, Carlson BL, Hu Z, Decker PA, Eckel-Passow JE, Burgenske DM, Zhong W, Trzasko JD, Herman MG, Elmquist WF, Remmes NB, Sarkaria JN

Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors.

Rathi S, Mladek AC, Oh JH, Dragojevic S, Burgenske DM, Zhang W, Talele S, Zhang W, Bakken KK, Carlson BL, Connors MA, He L, Hu Z, Sarkaria JN, Elmquist WF

Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models.

Jain S, Griffith JI, Porath KA, Rathi S, Le J, Pasa TI, Decker PA, Gupta SK, Hu Z, Carlson BL, Bakken K, Burgenske DM, Feldsien TM, Lefebvre DR, Vaubel RA, Eckel-Passow JE, Reilly EB, Elmquist WF, Sarkaria JN

ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma.

Laverty DJ, Gupta SK, Bradshaw GA, Hunter AS, Carlson BL, Calmo NM, Chen J, Tian S, Sarkaria JN, Nagel ZD

Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts.

Ji J, Dragojevic S, Callaghan CM, Smith EJ, Talele S, Zhang W, Connors MA, Mladek AC, Hu Z, Bakken KK, Sarkaria PP, Carlson BL, Burgenske DM, Decker PA, Rashid MA, Jang MH, Gupta SK, Eckel-Passow JE, Elmquist WF, Sarkaria JN